Scaling Approaches for Pediatric Dose Selection: The Fremanezumab (AJOVY^®) Journey to Select a Phase 3 Dose Using Pharmacokinetic Data from a Phase 1 Study

• Main Authors: Aksana Jones (Author), Orit Cohen-Barak (Author), Andrijana Radivojevic (Author), Jill Fiedler-Kelly (Author)
• Format: Book
• Published: MDPI AG, 2021-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Fremanezumab, a fully humanized IgG2Δa/kappa monoclonal antibody, selectively targets the calcitonin-gene-related peptide (CGRP) and prevents it from binding to the CGRP receptor. The safety, tolerability, pharmacokinetics (PK), and efficacy of fremanezumab for treating migraines administered as a o...